UNITY Biotechnology to Present Clinical Data at the Association for Research in Vision & Ophthalmology (ARVO) 2022 Annual Meeting

UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that clinical data results from the Phase 1 study of its lead senolytic candidate, UBX1325, in patients with diabetic macular edema and wet age-related macular degeneration will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting, being held May 1-4, 2022. Przemyslaw (Mike) Sapieha, Ph.D., chief scientific advisor for UNITY, will also participate in a symposium talk to discuss the potential correlation between cellular senescence and eye diseases, alongside other scientific leaders in the space. Details of the presentations are as follows:

Title: Cellular senescence and immune response in ocular health and disease
Session: Symposium
Date & Time: Sunday, May 1 at 8:00-10:00 a.m. MT
Speakers: James L. Kirkland, Cintia S. De Paiva, Rajendra Apte, Dorota Skowronska-Krawczyk, Mike Sapieha, and Raj Maturi

Title: UBX1325, a novel senolytic treatment for patients with advanced DME or wet AMD: 24-week results of a phase 1 study
Session: Paper presentation – AMD and retinal physiology
Date & Time: Wednesday, May 4 at 3:51-4:08 p.m. MT
Presenter: Robert Bhisitkul, M.D., Ph.D., professor of ophthalmology and director of the Retina Fellowship at University of California, San Francisco

Full presentations will be available virtually to ARVO participants starting May 1, 2022, at 7:00 a.m. ET. A recording of the presentation and symposium talks will be available on the ARVO website on May 11, 2022.

About UBX1325
UBX1325 is an investigational compound being studied for age-related diseases of the eye, including diabetic macular edema (DME), age-related macular degeneration (AMD), and diabetic retinopathy (DR) that is not approved for any use in any country. UBX1325 is a potent small molecule inhibitor of Bcl-xL, a member of the Bcl-2 family of apoptosis regulating proteins. UBX1325 is designed to inhibit the function of proteins that senescent cells rely on for survival. In a Phase 1 clinical study in advanced vascular eye disease, UBX1325 has shown a favorable safety profile and improvements in visual acuity sustained through 24 weeks following a single dose. In preclinical studies, UNITY has demonstrated that targeting Bcl-xL with UBX1325 preferentially eliminated senescent cells from diseased tissue while sparing cells in healthy tissue. UNITY’s goal with UBX1325 is to transformationally improve real-world outcomes for patients with DME, AMD, and DR.

About UNITY
UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases.